CR20150159A - Derivados oxazolidinona 3,4-disustituidos y su uso como inhibidores de potasio calcio activado - Google Patents

Derivados oxazolidinona 3,4-disustituidos y su uso como inhibidores de potasio calcio activado

Info

Publication number
CR20150159A
CR20150159A CR20150159A CR20150159A CR20150159A CR 20150159 A CR20150159 A CR 20150159A CR 20150159 A CR20150159 A CR 20150159A CR 20150159 A CR20150159 A CR 20150159A CR 20150159 A CR20150159 A CR 20150159A
Authority
CR
Costa Rica
Prior art keywords
oxazolidinona
inhibitors
derivatives
disposed
calcium activated
Prior art date
Application number
CR20150159A
Other languages
English (en)
Inventor
Luke Green
Haiyan Wang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20150159A publication Critical patent/CR20150159A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

La invención proporciona compuestos que tienen ña fórmula genral I
CR20150159A 2012-10-29 2015-03-20 Derivados oxazolidinona 3,4-disustituidos y su uso como inhibidores de potasio calcio activado CR20150159A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12190319 2012-10-29
PCT/EP2013/072361 WO2014067861A1 (en) 2012-10-29 2013-10-25 3,4-disubstituted oxazolidinone derivatives and their use as inhibitors of the calcium activated potassium channel

Publications (1)

Publication Number Publication Date
CR20150159A true CR20150159A (es) 2015-04-30

Family

ID=47143594

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20150159A CR20150159A (es) 2012-10-29 2015-03-20 Derivados oxazolidinona 3,4-disustituidos y su uso como inhibidores de potasio calcio activado

Country Status (24)

Country Link
US (1) US9611232B2 (es)
EP (1) EP2912034B1 (es)
JP (1) JP6216385B2 (es)
KR (1) KR20150075091A (es)
CN (1) CN104781256B (es)
AR (1) AR093168A1 (es)
AU (1) AU2013339607A1 (es)
BR (1) BR112015003996A2 (es)
CA (1) CA2879249A1 (es)
CL (1) CL2015000906A1 (es)
CO (1) CO7170170A2 (es)
CR (1) CR20150159A (es)
EA (1) EA026161B1 (es)
HK (1) HK1207632A1 (es)
IL (1) IL237331A0 (es)
IN (1) IN2015DN00961A (es)
MA (1) MA38135B1 (es)
MX (1) MX2015002399A (es)
PE (1) PE20150775A1 (es)
PH (1) PH12015500292A1 (es)
SG (1) SG11201500585XA (es)
TW (1) TW201422596A (es)
UA (1) UA114649C2 (es)
WO (1) WO2014067861A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102047502B1 (ko) * 2016-06-20 2019-11-22 셀라이온바이오메드 주식회사 포타슘 채널 단백질을 이용한 암 진단용 조성물
WO2020193419A1 (en) 2019-03-22 2020-10-01 Saniona A/S Novel potassium channel inhibitors
US20240034717A1 (en) 2020-09-22 2024-02-01 Saniona A/S Novel potassium channel inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2538424C2 (de) * 1975-08-29 1983-01-05 Nordmark-Werke Gmbh, 2000 Hamburg 4-substituierte 5-Phenyl-oxazolidon-(2)- Verbindungen und ein diese enthaltendes pharmazeutisches Präparat
KR940006634B1 (ko) * 1985-09-09 1994-07-23 오쓰까 세이야꾸 가부시끼가이샤 2-옥사-이소세펨 화합물의 제조방법
KR930703262A (ko) * 1990-11-06 1993-11-29 스튜어트 알. 슈터 이미다졸리디논 화합물
DE4439846A1 (de) * 1994-11-08 1996-05-09 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
AU1812197A (en) * 1996-03-01 1997-09-16 Sankyo Company Limited Hydroxamic acid derivatives
NZ511334A (en) * 1998-12-04 2003-06-30 Neurosearch As Benzimidazolone derivatives useful as ion channel modulating agents
WO2001053258A1 (fr) * 2000-01-20 2001-07-26 Eisai Co., Ltd. Composes azotes cycliques et compositions pharmaceutiques les contenant
JP3966693B2 (ja) * 2000-01-20 2007-08-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 含窒素環化合物およびそれらを含んでなる医薬組成物
JP4295505B2 (ja) * 2000-11-22 2009-07-15 バイエル アクチェンゲゼルシャフト 新規なラクタム置換ピラゾロピリジン誘導体
JP4719745B2 (ja) 2004-07-29 2011-07-06 メルク・シャープ・エンド・ドーム・コーポレイション カリウムチャンネル阻害剤
DE102004060229A1 (de) * 2004-12-15 2006-06-29 Sanofi-Aventis Deutschland Gmbh Neue zyklische Harnstoffe als Inhibitoren von Metallproteasen
US7378530B2 (en) * 2005-02-22 2008-05-27 Nereus Pharmaceuticals, Inc. Anti-cancer and anti-microbial 5-membered heterocyclic compounds
US20100056637A1 (en) 2005-12-20 2010-03-04 Icagen, Inc. Treatment methods using triaryl methane compounds
WO2007109098A2 (en) * 2006-03-16 2007-09-27 Azevan Pharmaceuticals, Inc. HYDROXY AND KETO-SUBSTITUTED β-LACTAMYL ALKANEDIOIC ACIDS
TW201026708A (en) 2008-12-12 2010-07-16 Solvay Pharm Bv Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers
WO2010123997A1 (en) * 2009-04-22 2010-10-28 Achaogen, Inc. Carbacephem beta-lactam antibiotics

Also Published As

Publication number Publication date
EA026161B1 (ru) 2017-03-31
EP2912034B1 (en) 2017-05-31
HK1207632A1 (en) 2016-02-05
EA201590729A1 (ru) 2015-07-30
CO7170170A2 (es) 2015-01-28
PH12015500292A1 (en) 2015-04-20
US20150246894A1 (en) 2015-09-03
JP6216385B2 (ja) 2017-10-18
WO2014067861A1 (en) 2014-05-08
US9611232B2 (en) 2017-04-04
AR093168A1 (es) 2015-05-20
JP2015535231A (ja) 2015-12-10
MA38135A2 (fr) 2016-11-30
AU2013339607A1 (en) 2015-02-05
EP2912034A1 (en) 2015-09-02
UA114649C2 (uk) 2017-07-10
SG11201500585XA (en) 2015-04-29
CA2879249A1 (en) 2014-05-08
PE20150775A1 (es) 2015-05-21
MX2015002399A (es) 2015-06-10
CN104781256B (zh) 2017-09-29
IL237331A0 (en) 2015-04-30
IN2015DN00961A (es) 2015-06-12
KR20150075091A (ko) 2015-07-02
MA38135B1 (fr) 2018-11-30
BR112015003996A2 (pt) 2017-07-04
TW201422596A (zh) 2014-06-16
CL2015000906A1 (es) 2015-09-11
CN104781256A (zh) 2015-07-15

Similar Documents

Publication Publication Date Title
CR20140501A (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos
UA108101C2 (xx) Похідні n3-заміщених n1-сульфоніл-5-фторпіримідинонів
CR20150120A (es) Nuevos derivados bicíclicos
SMT201600198B (it) Derivati di 1,2,4-triazina-4-ammina
CR20140106A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
CR20150462A (es) Inhibidores de erk y sus usos
EA201270257A1 (ru) Производные n1-сульфонил-5-фторпиримидинона
CO2018000631A2 (es) Compuestos bicíclicos como inhibidores de atx
CR20180057A (es) Nuevos compuestos biciclicos como inhibidores duales de atx/ca.
CR20150436A (es) Nuevos octahidro-pirrolo[3,4-c]-pirrol y -piridina-fenilo
CR20140229A (es) Nuevos derivados bicíclicos de dihidroisoquinolin-1-ona
ECSP14033037A (es) Síntesis de compuestos heterocíclicos
CR20130045A (es) Compuestos terapéuticos
UY34602A (es) ?Derivados de bencimidazolil- e imidazopiridinil-metilamina?
NI201200023A (es) Derivados de 5-fluoropirimidinona
BR112016006319A2 (pt) inibidores de irak e usos dos mesmos
UY36330A (es) Compuestos inhibidores de quinasa de unión a tank
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
CR20160171A (es) NUEVO OCTAHIDRO-CICLOBUTA[1,2-c; 3,4-c] DIPIRROL-2-ILO
CR20150470A (es) Derivados de triazolona de piridinilo y piridinilo fusionado
CY1122115T1 (el) Παραγωγα ν1-ακυλο-5-φθοροπυριμιδινονης
BR112013006016A2 (pt) compostos de azabenzotiazol, composições e métodos de uso
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
UY34636A (es) Composiciones tópicas que comprenden fipronilo y permetrina y sus métodos de uso
CR20140135A (es) Nuevos derivados de aril-quinolina